• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2.

作者信息

Ahn Terrie S, Han Brandon, Krogstad Paul, Bun Chantana, Kohn Lisa A, Garcia-Lloret Maria I, Damoiseaux Robert, Butte Manish J

机构信息

Division of Immunology, Allergy, and Rheumatology, Department of Pediatrics, University of California Los Angeles, Los Angeles, Calif.

Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, Calif; California NanoSystems Institute, University of California Los Angeles, Los Angeles, Calif.

出版信息

J Allergy Clin Immunol. 2021 Mar;147(3):876-877. doi: 10.1016/j.jaci.2020.12.003. Epub 2020 Dec 17.

DOI:10.1016/j.jaci.2020.12.003
PMID:33358557
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7833834/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ce3/7833834/e7dbaf7fbbaa/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ce3/7833834/e7dbaf7fbbaa/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ce3/7833834/e7dbaf7fbbaa/gr1_lrg.jpg

相似文献

1
Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2.商业免疫球蛋白产品含有针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的交叉反应性但无中和作用的抗体。
J Allergy Clin Immunol. 2021 Mar;147(3):876-877. doi: 10.1016/j.jaci.2020.12.003. Epub 2020 Dec 17.
2
Characterization of SARS-CoV-2-specific antibodies in COVID-19 patients reveals highly potent neutralizing IgA.对新冠病毒肺炎患者中新冠病毒2型特异性抗体的表征揭示了高效中和性IgA。
Signal Transduct Target Ther. 2021 Jan 29;6(1):35. doi: 10.1038/s41392-021-00478-7.
3
Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).由SARS-CoV-2 501Y.V2（B.1.351）引发的交叉反应性中和抗体反应
N Engl J Med. 2021 Jun 3;384(22):2161-2163. doi: 10.1056/NEJMc2104192. Epub 2021 Apr 7.
4
Structure-based development of human antibody cocktails against SARS-CoV-2.基于结构的抗SARS-CoV-2人源抗体鸡尾酒疗法的开发。
Cell Res. 2021 Jan;31(1):101-103. doi: 10.1038/s41422-020-00446-w. Epub 2020 Dec 1.
5
Neutralizing SARS-CoV-2.中和 SARS-CoV-2
Elife. 2020 Dec 15;9:e64496. doi: 10.7554/eLife.64496.
6
Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants.疫苗诱导产生的抗体水平与针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）及其变体的中和活性之间的相关性。
Clin Transl Med. 2021 Dec;11(12):e644. doi: 10.1002/ctm2.644.
7
Distinct neutralization profile of spike variants by antibodies induced upon SARS-CoV-2 infection or vaccination.SARS-CoV-2感染或疫苗接种诱导产生的抗体对刺突蛋白变体的独特中和谱。
Am J Hematol. 2022 Jan 1;97(1):E3-E7. doi: 10.1002/ajh.26380. Epub 2021 Nov 5.
8
Fc effector cross-reactivity: A hidden arsenal against SARS-CoV-2's evasive maneuvering.Fc 效应器交叉反应性：对抗 SARS-CoV-2 逃避策略的隐藏武器。
Cell Rep Med. 2022 Feb 8;3(2):100540. doi: 10.1016/j.xcrm.2022.100540. eCollection 2022 Feb 15.
9
Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine.一种灭活的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒疫苗诱导的中和抗体的分子去卷积分析
Protein Cell. 2021 Oct;12(10):818-823. doi: 10.1007/s13238-021-00840-z. Epub 2021 Apr 28.
10
Spike Protein Antibodies Mediate the Apparent Correlation between SARS-CoV-2 Nucleocapsid Antibodies and Neutralization Test Results.刺突蛋白抗体介导了SARS-CoV-2核衣壳抗体与中和试验结果之间的明显相关性。
Microbiol Spectr. 2021 Sep 3;9(1):e0021821. doi: 10.1128/Spectrum.00218-21. Epub 2021 Jun 16.

引用本文的文献

1
An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity.提高免疫缺陷患者中针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）特异性免疫的策略概述
Vaccines (Basel). 2024 Jun 18;12(6):675. doi: 10.3390/vaccines12060675.
2
Intravenous immunoglobulins for the treatment of prolonged COVID-19 in immunocompromised patients: a brief report.静脉注射免疫球蛋白治疗免疫功能低下患者的持续性 COVID-19：简要报告。
Front Immunol. 2024 Apr 19;15:1399180. doi: 10.3389/fimmu.2024.1399180. eCollection 2024.
3
Infections in Inborn Errors of Immunity with Combined Immune Deficiency: A Review.

本文引用的文献

1
Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens.目前可用的静脉用免疫球蛋白含有针对严重急性呼吸综合征冠状病毒 2 抗原的抗体。
Immunotherapy. 2020 Jun;12(8):571-576. doi: 10.2217/imt-2020-0095. Epub 2020 May 12.
2
Successful treatment with plasma exchange followed by intravenous immunoglobulin in a critically ill patient with COVID-19.COVID-19 危重症患者采用血浆置换联合静脉注射免疫球蛋白治疗获得成功。
Int J Antimicrob Agents. 2020 Aug;56(2):105974. doi: 10.1016/j.ijantimicag.2020.105974. Epub 2020 Apr 13.
3
Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19.
先天性免疫缺陷合并免疫缺陷中的感染：综述
Pathogens. 2023 Feb 7;12(2):272. doi: 10.3390/pathogens12020272.
4
Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant.商业免疫球蛋白产品中的中和 SARS-CoV-2 抗体使 X 连锁无丙种球蛋白血症患者对奥密克戎变异株的被动免疫有限。
J Clin Immunol. 2022 Aug;42(6):1130-1136. doi: 10.1007/s10875-022-01283-9. Epub 2022 May 11.
常规静脉注射免疫球蛋白治疗对新型冠状病毒肺炎（COVID-19）重症肺炎患者预后的影响。
J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.03.044. Epub 2020 Apr 10.
4
High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019.大剂量静脉注射免疫球蛋白作为新型冠状病毒肺炎病情恶化患者的一种治疗选择
Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102. doi: 10.1093/ofid/ofaa102. eCollection 2020 Mar.
5
A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV.SARS-CoV-2 和 SARS 冠状病毒受体结合域中高度保守的隐蔽表位。
Science. 2020 May 8;368(6491):630-633. doi: 10.1126/science.abb7269. Epub 2020 Apr 3.
6
Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review.目前的治疗选择和肽作为中东呼吸综合征（MERS）潜在治疗成分的作用：综述。
J Infect Public Health. 2018 Jan-Feb;11(1):9-17. doi: 10.1016/j.jiph.2017.08.009. Epub 2017 Aug 31.
7
Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses.静脉注射免疫球蛋白中交叉反应性流感特异性抗体依赖性细胞毒性作为对抗新出现流感病毒的潜在疗法。
J Infect Dis. 2014 Dec 1;210(11):1811-22. doi: 10.1093/infdis/jiu334. Epub 2014 Jun 10.